- Home
- KRUS vs COGT Comparison
KRUS vs COGT Comparison
Compare KRUS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- COGT
- Stock Information
- Founded
- KRUS 2008
- COGT 2014
- Country
- KRUS United States
- COGT United States
- Employees
- KRUS N/A
- COGT N/A
- Industry
- KRUS Restaurants
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- COGT Health Care
- Exchange
- KRUS Nasdaq
- COGT Nasdaq
- Market Cap
- KRUS 990.5M
- COGT 806.1M
- IPO Year
- KRUS 2019
- COGT 2018
- Fundamental
- Price
- KRUS $90.76
- COGT $7.58
- Analyst Decision
- KRUS Buy
- COGT Buy
- Analyst Count
- KRUS 9
- COGT 6
- Target Price
- KRUS $76.78
- COGT $15.20
- AVG Volume (30 Days)
- KRUS 278.5K
- COGT 2.5M
- Earning Date
- KRUS 07-08-2025
- COGT 08-05-2025
- Dividend Yield
- KRUS N/A
- COGT N/A
- EPS Growth
- KRUS N/A
- COGT N/A
- EPS
- KRUS N/A
- COGT N/A
- Revenue
- KRUS $258,444,000.00
- COGT N/A
- Revenue This Year
- KRUS $19.52
- COGT N/A
- Revenue Next Year
- KRUS $18.63
- COGT N/A
- P/E Ratio
- KRUS N/A
- COGT N/A
- Revenue Growth
- KRUS 21.37
- COGT N/A
- 52 Week Low
- KRUS $40.03
- COGT $3.72
- 52 Week High
- KRUS $110.66
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- KRUS 74.66
- COGT 66.59
- Support Level
- KRUS $79.15
- COGT $7.07
- Resistance Level
- KRUS $91.14
- COGT $7.50
- Average True Range (ATR)
- KRUS 3.60
- COGT 0.44
- MACD
- KRUS 0.57
- COGT -0.04
- Stochastic Oscillator
- KRUS 97.54
- COGT 73.99
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.